FDA Investigation Leads to Charges in Counterfeit Ozempic Scheme
The U.S. Department of Justice and the U.S. Attorney’s Office for the Middle District of Florida announced federal charges against two Indian nationals involved in a transnational counterfeit prescription drug distribution scheme. The investigation, assisted by the FDA's Office of Criminal Investigations, revealed that the defendants allegedly obtained counterfeit Ozempic from unauthorized sources in China and distributed it with fraudulent packaging and needles to U.S. distributors and pharmacies at deeply discounted prices.
Court documents indicate that the distribution of these falsified products continued even after the FDA issued public safety alerts and seizures regarding counterfeit Ozempic. The FDA advises healthcare providers and consumers to remain vigilant against counterfeit medications and to report suspicious products directly to the agency.
Key points
- Two individuals were charged with conspiracy and smuggling in a counterfeit drug scheme.
- Counterfeit Ozempic with fake packaging and labels was distributed to downstream customers and pharmacies.
- The illegal distribution reportedly persisted despite prior FDA safety warnings and product seizures.
What it means for you
This case highlights ongoing global risks regarding counterfeit diabetes therapies entering distribution channels. Clinicians and pharmacists should remain vigilant for falsified products, purchase supplies exclusively through verified and authorized channels, and check with DRAP for local availability and guidance.
FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.